The anti-EGFR antibody mixture Sym004 overcomes acquired resistance to cetuximab in colorectal cancer

被引：0
|
作者：
Sanchez-Martin, Francisco J.
Dalmases, Alba
Bellosillo, Beatriz
Argiles, Guillem
Gelabert, Mariona
Canadas, Israel
Vidal, Joana
Siravegna, Giulia
Arena, Sabrina
Koefoed, Klaus
Visa, Laura
Arpf, Oriol
Horak, Ivan D.
Iglesias, Mar
Stroh, Christopher
Kragh, Michael
Rovira, Ana
Albanell, Joan
Bardelli, Alberto
Tabernero, Josep
Montagut, Clara
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-2149
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2149
引用
收藏
页数：3
相关论文
共 50 条
  • [1] The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
    Sanchez-Martin, Francisco J.
    Bellosillo, Beatriz
    Gelabert-Baldrich, Mariona
    Dalmases, Alba
    Canadas, Israel
    Vidal, Joana
    Martinez, Alejandro
    Argiles, Guillem
    Siravegna, Giulia
    Arena, Sabrina
    Koefoed, Klaus
    Visa, Laura
    Arpi, Oriol
    Horak, Ivan David
    Iglesias, Mar
    Stroh, Christopher
    Kragh, Michael
    Rovira, Ana
    Albanell, Joan
    Tabernero, Josep
    Bardelli, Alberto
    Montagut, Clara
    CLINICAL CANCER RESEARCH, 2016, 22 (13) : 3260 - 3267
  • [2] Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab
    Iida, Mari
    Brand, Toni M.
    Starr, Megan M.
    Li, Chunrong
    Huppert, Evan J.
    Luthar, Neha
    Pedersen, Mikkel W.
    Horak, Ivan D.
    Kragh, Michael
    Wheeler, Deric L.
    NEOPLASIA, 2013, 15 (10): : 1182 - 1192
  • [3] Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation
    Napolitano, Stefania
    Martini, Giulia
    Martinelli, Erika
    Belli, Valentina
    Parascandolo, Alessia
    Laukkanen, Mikko O.
    Sforza, Vincenzo
    Morgillo, Floriana
    Ciardiello, Davide
    Ciardiello, Fortunato
    Troiani, Teresa
    ONCOTARGET, 2017, 8 (40) : 67592 - 67604
  • [4] Sym004: A novel synergistic anti-EGFR antibody mixture with superior anti-cancer efficacy
    Dienstmann, R.
    Patnaik, A.
    Tolcher, A. W.
    Pedersen, M. W.
    Jacobsen, H. J.
    Kofoed, K.
    Petersen, J.
    Tabernero, J.
    Kragh, M.
    ANNALS OF ONCOLOGY, 2011, 22 : 22 - 22
  • [5] Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
    Dienstmann, Rodrigo
    Patnaik, Amita
    Garcia-Carbonero, Rocio
    Cervantes, Andres
    Benavent, Marta
    Rosello, Susana
    Tops, Bastiaan B. J.
    van der Post, Rachel S.
    Argiles, Guillem
    Skartved, Niels J. O.
    Hansen, Ulla H.
    Hald, Rikke
    Pedersen, Mikkel W.
    Kragh, Michael
    Horak, Ivan D.
    Braun, Stephan
    Van Cutsem, Eric
    Tolcher, Anthony W.
    Tabernero, Josep
    CANCER DISCOVERY, 2015, 5 (06) : 598 - 609
  • [6] The role of Sym004, a novel EGFR antibody mixture, in patients with refractory colorectal cancer
    Fountzilas, Elena
    Pentheroudakis, George
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S87 - S90
  • [7] SYM004, a novel generation anti-EGFR inhibitor, is able to overcome acquired resistance to cetuximab such as MET activation, ERBB2 amplification and EGFR mutations, in colorectal cancer models
    Napolitano, S.
    Belli, V.
    Castellone, M. D.
    Parascandolo, A.
    Martinelli, E.
    Martini, G.
    Cardone, C.
    Morgillo, F.
    Orditura, M.
    Ciardiello, F.
    Troiani, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] SYM004 Anti-EGFR monoclonal antibodies Antitumor agent
    Morris, Z. S.
    Francis, D. M.
    Huang, S.
    Harari, P. M.
    DRUGS OF THE FUTURE, 2015, 40 (06) : 371 - 380
  • [9] Sym004: Truly a New Level of Anti-EGFR Treatment?
    Stintzing, Sebastian
    Heinemann, Volker
    CANCER DISCOVERY, 2015, 5 (06) : 578 - 580
  • [10] Sym004 to circumvent resistance to cetuximab driven by emergence of EGFR extracellular mutations in colorectal cancer.
    Montagut, Clara
    Canadas, Israel
    Gavilan, Elena
    Arpi, Oriol
    Bellosillo, Beatriz
    Martinez, Alejandro
    Dalmases, Alba
    Rovira, Ana
    Albanell, Joan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345